ITK and B-cell non-Hodgkin lymphoma: Given the success of the BTK inhibitor ibrutinib in the treatment of B cell lymphoma, the TEC family member ITK has become an appealing target for inhibiting TCR signaling, which plays an important role in T cell activation, development, differentiation, and cytokines production [15, 16].